...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Nanomedicine >Liposome delivery systems for the treatment of Alzheimer’s disease
【24h】

Liposome delivery systems for the treatment of Alzheimer’s disease

机译：用于治疗阿尔茨海默氏病的脂质体递送系统

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Alzheimer’s disease (AD) will affect around 115?million people worldwide by the year 2050. It is associated with the accumulation of misfolded and aggregated proteins (β-amyloid and tau) in the senile plaques and neurofibrillary tangles found in the brain. Currently available drugs for AD only temporarily alleviate symptoms and do not slow the inevitable progression of this disease. New drugs are required that act on key pathologies in order to arrest or reverse cognitive decline. However, there has been a spectacular failure rate in clinical trials of conventional small molecule drugs or biological agents. Targeted nanoliposomes represent a viable and promising drug delivery system for AD that have not yet reached clinical trials. They are biocompatible, highly flexible, and have the potential to carry many different types of therapeutic molecules across the blood–brain barrier (BBB) and into brain cells. They can be tailored to extend blood circulation time and can be directed against individual or multiple pathological targets. Modifications so far have included the use of brain-penetrating peptides, together with Aβ-targeting ligands, such as phosphatidic acid, curcumin, and a retro-inverted peptide that inhibits Aβ aggregation. Combining several modifications together into multifunctional liposomes is currently a research area of great interest. This review focuses on recent liposomal approaches to AD therapy, including mechanisms involved in facilitating their passage across the BBB, and the evaluation of new therapeutic agents for blocking Aβ and/or tau aggregation.
机译：到2050年，阿尔茨海默氏病（AD）将影响全世界约1.15亿人。这与大脑斑块和大脑中发现的神经原纤维缠结中错误折叠和聚集的蛋白质（β-淀粉样蛋白和tau蛋白）的积累有关。目前可用的AD药物只能暂时缓解症状，并且不会减慢该疾病不可避免的进展。为了阻止或逆转认知能力下降，需要对关键病理起作用的新药。但是，在常规小分子药物或生物制剂的临床试验中，失败率很高。靶向的纳米脂质体代表了尚未到达临床试验的可行且有前途的AD药物递送系统。它们具有生物相容性，高度灵活性，并具有将多种不同类型的治疗分子跨过血脑屏障（BBB）并进入脑细胞的潜力。可以对它们进行定制以延长血液循环时间，并且可以针对单个或多个病理目标。迄今为止的修饰包括使用脑穿透肽以及靶向Aβ的配体，例如磷脂酸，姜黄素和抑制Aβ聚集的逆转肽。将几种修饰结合在一起成为多功能脂质体是当前非常感兴趣的研究领域。这篇综述的重点是最近的AD治疗脂质体方法，包括促进其通过BBB通道的机制，以及评估用于阻断Aβ和/或tau聚集的新治疗剂的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号